Rankings
▼
Calendar
VRDN FY 2025 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
VRDN
Viridian Therapeutics, Inc.
$3B
FY 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$71M
+23359.9% YoY
Gross Profit
$70M
98.4% margin
Operating Income
-$363M
-512.9% margin
Net Income
-$343M
-483.6% margin
EPS (Diluted)
$-3.32
Cash Flow
Operating Cash Flow
-$276M
Free Cash Flow
-$277M
Stock-Based Comp.
$44M
Balance Sheet
Total Assets
$899M
Total Liabilities
$177M
Stockholders' Equity
$722M
Cash & Equivalents
$212M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$71M
$302,000
+23359.9%
Gross Profit
$70M
$302,000
+22975.8%
Operating Income
-$363M
-$299M
-21.5%
Net Income
-$343M
-$270M
-26.9%
← Q4 2024
All Quarters
Q1 2025 →